{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:05:04Z","timestamp":1767704704784},"reference-count":78,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With many available data sources, clinicians need to consider the benefit\u2010risk profile of individual anticoagulants when balancing the need for anticoagulation, including evaluating the risks in patients with comorbidities and potential drug\u2010drug interactions. This narrative review presents clinical data across multiple phases of drug development for the use of apixaban, a selective factor Xa inhibitor, when taken concomitantly with other agents, and evaluates the benefit\u2010risk profile of apixaban with these interacting medications. Key subgroup analyses from the phase 3 ARISTOTLE trial (NCT00412984) are presented using data from patients who received either concomitant inhibitors or inducers of cytochrome P450 3A4 and\/or P\u2011glycoprotein. We also review the available evidence for the use of apixaban in patients with cancer\u2010associated thromboembolism, as well as the use of apixaban in patients with COVID\u201019.<\/jats:p>","DOI":"10.1002\/cpdd.1446","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T14:21:20Z","timestamp":1721830880000},"page":"961-973","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Implications of Co\u2010administering Apixaban with Key Interacting Medications"],"prefix":"10.1002","volume":"13","author":[{"given":"Nicholas","family":"Favatella","sequence":"first","affiliation":[{"name":"Bristol Myers Squibb  Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dalton","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonkyung","family":"Byon","sequence":"additional","affiliation":[{"name":"Pfizer  Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira J.","family":"Merali","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Klem","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_16_2_1","DOI":"10.1136\/bmjqs-2012-001748"},{"doi-asserted-by":"publisher","key":"e_1_2_16_3_1","DOI":"10.1093\/eurheartj\/ehaa612"},{"doi-asserted-by":"publisher","key":"e_1_2_16_4_1","DOI":"10.1016\/j.jacc.2019.01.011"},{"doi-asserted-by":"publisher","key":"e_1_2_16_5_1","DOI":"10.1056\/NEJMoa1107039"},{"doi-asserted-by":"publisher","key":"e_1_2_16_6_1","DOI":"10.1056\/NEJMoa1007432"},{"doi-asserted-by":"publisher","key":"e_1_2_16_7_1","DOI":"10.1056\/NEJMoa1006885"},{"doi-asserted-by":"publisher","key":"e_1_2_16_8_1","DOI":"10.1016\/S0140-6736(09)62125-5"},{"doi-asserted-by":"publisher","key":"e_1_2_16_9_1","DOI":"10.1056\/NEJMoa1302507"},{"doi-asserted-by":"publisher","key":"e_1_2_16_10_1","DOI":"10.1056\/NEJMoa1207541"},{"doi-asserted-by":"publisher","key":"e_1_2_16_11_1","DOI":"10.1093\/jpp\/rgab102"},{"doi-asserted-by":"publisher","key":"e_1_2_16_12_1","DOI":"10.1111\/bcp.12106"},{"issue":"7","key":"e_1_2_16_13_1","first-page":"564","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects","volume":"52","author":"Yamahira N","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"doi-asserted-by":"publisher","key":"e_1_2_16_14_1","DOI":"10.1111\/j.1365-2125.2012.04369.x"},{"doi-asserted-by":"publisher","key":"e_1_2_16_15_1","DOI":"10.1177\/1076029612441859"},{"doi-asserted-by":"publisher","key":"e_1_2_16_16_1","DOI":"10.1007\/s40262-019-00775-z"},{"doi-asserted-by":"publisher","key":"e_1_2_16_17_1","DOI":"10.1055\/s-0038-1627480"},{"doi-asserted-by":"publisher","key":"e_1_2_16_18_1","DOI":"10.1007\/s11239-011-0551-3"},{"doi-asserted-by":"publisher","key":"e_1_2_16_19_1","DOI":"10.1002\/jcph.1097"},{"doi-asserted-by":"publisher","key":"e_1_2_16_20_1","DOI":"10.1002\/cpdd.990"},{"doi-asserted-by":"publisher","key":"e_1_2_16_21_1","DOI":"10.1007\/s40256-015-0157-9"},{"doi-asserted-by":"publisher","key":"e_1_2_16_22_1","DOI":"10.1124\/dmd.112.050260"},{"doi-asserted-by":"publisher","key":"e_1_2_16_23_1","DOI":"10.1111\/bcp.12541"},{"doi-asserted-by":"publisher","key":"e_1_2_16_24_1","DOI":"10.1124\/dmd.108.023143"},{"doi-asserted-by":"publisher","key":"e_1_2_16_25_1","DOI":"10.1124\/dmd.109.029694"},{"doi-asserted-by":"publisher","key":"e_1_2_16_26_1","DOI":"10.1111\/j.1755-5922.2009.00111.x"},{"doi-asserted-by":"publisher","key":"e_1_2_16_27_1","DOI":"10.1136\/openhrt-2017-000712"},{"doi-asserted-by":"publisher","key":"e_1_2_16_28_1","DOI":"10.1111\/bcp.12393"},{"doi-asserted-by":"publisher","key":"e_1_2_16_29_1","DOI":"10.1007\/s40256-019-00348-2"},{"key":"e_1_2_16_30_1","first-page":"19","article-title":"The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects","volume":"9","author":"Frost C","year":"2017","journal-title":"Clin Pharmacol"},{"doi-asserted-by":"publisher","key":"e_1_2_16_31_1","DOI":"10.1016\/j.jacc.2014.03.022"},{"doi-asserted-by":"publisher","key":"e_1_2_16_32_1","DOI":"10.1186\/1479-7364-5-1-61"},{"doi-asserted-by":"publisher","key":"e_1_2_16_33_1","DOI":"10.1016\/S0735-1097(17)33831-7"},{"doi-asserted-by":"publisher","key":"e_1_2_16_34_1","DOI":"10.3389\/fnagi.2022.791285"},{"doi-asserted-by":"publisher","key":"e_1_2_16_35_1","DOI":"10.1111\/bcp.14227"},{"issue":"3","key":"e_1_2_16_36_1","article-title":"Risk of bleeding in patients with non\u2010valvular atrial fibrillation exposed to apixaban with or without selective serotonin reuptake inhibitors (SSRIs) or serotonin\u2010norepinephrine reuptake inhibitors (SNRIs)","volume":"142","author":"Shen SW","year":"2020","journal-title":"Circulation"},{"doi-asserted-by":"publisher","key":"e_1_2_16_37_1","DOI":"10.1016\/j.jacc.2014.07.967"},{"doi-asserted-by":"publisher","key":"e_1_2_16_38_1","DOI":"10.1046\/j.1365-2125.2000.00134.x"},{"doi-asserted-by":"publisher","key":"e_1_2_16_39_1","DOI":"10.1055\/s-0038-1676983"},{"doi-asserted-by":"publisher","key":"e_1_2_16_40_1","DOI":"10.1056\/NEJMoa1915103"},{"doi-asserted-by":"publisher","key":"e_1_2_16_41_1","DOI":"10.1200\/JCO.19.01461"},{"doi-asserted-by":"publisher","key":"e_1_2_16_42_1","DOI":"10.1093\/eurheartj\/ehac244"},{"issue":"6","key":"e_1_2_16_43_1","first-page":"924","article-title":"Nephrotoxicity of anticancer treatment","volume":"32","author":"Malyszko J","year":"2017","journal-title":"Nephrol Dial Transplant"},{"doi-asserted-by":"publisher","key":"e_1_2_16_44_1","DOI":"10.1007\/s12094-018-02017-3"},{"doi-asserted-by":"publisher","key":"e_1_2_16_45_1","DOI":"10.1093\/annonc\/mdx225"},{"doi-asserted-by":"publisher","key":"e_1_2_16_46_1","DOI":"10.1056\/NEJMoa1814468"},{"doi-asserted-by":"publisher","key":"e_1_2_16_47_1","DOI":"10.1124\/dmd.118.083766"},{"doi-asserted-by":"publisher","key":"e_1_2_16_48_1","DOI":"10.2165\/00003088-200544110-00003"},{"volume-title":"Medical Genetics Summaries [Internet]","year":"2012","author":"Dean L","key":"e_1_2_16_49_1"},{"doi-asserted-by":"publisher","key":"e_1_2_16_50_1","DOI":"10.2165\/00003088-198916040-00002"},{"doi-asserted-by":"publisher","key":"e_1_2_16_51_1","DOI":"10.1016\/bs.acr.2021.03.008"},{"doi-asserted-by":"publisher","key":"e_1_2_16_52_1","DOI":"10.1016\/j.critrevonc.2006.09.006"},{"doi-asserted-by":"publisher","key":"e_1_2_16_53_1","DOI":"10.2165\/00003088-200645030-00002"},{"doi-asserted-by":"publisher","key":"e_1_2_16_54_1","DOI":"10.1016\/j.tranon.2021.101169"},{"doi-asserted-by":"publisher","key":"e_1_2_16_55_1","DOI":"10.1126\/science.959821"},{"doi-asserted-by":"publisher","key":"e_1_2_16_56_1","DOI":"10.1016\/S0006-2952(99)00410-4"},{"issue":"2","key":"e_1_2_16_57_1","first-page":"226","article-title":"Clinical pharmacology of cyclophosphamide","volume":"33","author":"Bagley CM","year":"1973","journal-title":"Cancer Res"},{"doi-asserted-by":"publisher","key":"e_1_2_16_58_1","DOI":"10.2217\/pgs.09.118"},{"doi-asserted-by":"publisher","key":"e_1_2_16_59_1","DOI":"10.1007\/BF00578558"},{"doi-asserted-by":"publisher","key":"e_1_2_16_60_1","DOI":"10.1136\/esmoopen-2017-000167"},{"volume-title":"Paclitaxel","year":"2024","author":"Awosika AO","key":"e_1_2_16_61_1"},{"doi-asserted-by":"publisher","key":"e_1_2_16_62_1","DOI":"10.2165\/00003088-199936020-00002"},{"doi-asserted-by":"publisher","key":"e_1_2_16_63_1","DOI":"10.2165\/00003088-198712040-00001"},{"doi-asserted-by":"publisher","key":"e_1_2_16_64_1","DOI":"10.1111\/jth.14662"},{"doi-asserted-by":"publisher","key":"e_1_2_16_65_1","DOI":"10.1016\/j.ejca.2021.02.026"},{"doi-asserted-by":"publisher","key":"e_1_2_16_66_1","DOI":"10.1007\/s40256-020-00431-z"},{"doi-asserted-by":"publisher","key":"e_1_2_16_67_1","DOI":"10.1001\/jama.2020.5394"},{"doi-asserted-by":"publisher","key":"e_1_2_16_68_1","DOI":"10.1016\/S0140-6736(20)30566-3"},{"doi-asserted-by":"publisher","key":"e_1_2_16_69_1","DOI":"10.1097\/CCM.0000000000004458"},{"doi-asserted-by":"publisher","key":"e_1_2_16_70_1","DOI":"10.1055\/a-1178-3551"},{"doi-asserted-by":"publisher","key":"e_1_2_16_71_1","DOI":"10.1055\/s-0040-1713152"},{"doi-asserted-by":"publisher","key":"e_1_2_16_72_1","DOI":"10.1016\/j.jacc.2020.04.031"},{"doi-asserted-by":"publisher","key":"e_1_2_16_73_1","DOI":"10.1016\/j.jacc.2020.04.016"},{"doi-asserted-by":"publisher","key":"e_1_2_16_74_1","DOI":"10.1177\/10600280211025042"},{"doi-asserted-by":"publisher","key":"e_1_2_16_75_1","DOI":"10.1111\/nyas.12567"},{"doi-asserted-by":"publisher","key":"e_1_2_16_76_1","DOI":"10.2165\/00003088-198611060-00005"},{"doi-asserted-by":"publisher","key":"e_1_2_16_77_1","DOI":"10.2165\/00003088-198916040-00003"},{"doi-asserted-by":"publisher","key":"e_1_2_16_78_1","DOI":"10.1007\/s10557-019-06907-8"},{"doi-asserted-by":"publisher","key":"e_1_2_16_79_1","DOI":"10.1007\/s11239-020-02037-3"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T01:55:29Z","timestamp":1725242129000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/cpdd.1446"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1446","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"type":"print","value":"2160-763X"},{"type":"electronic","value":"2160-7648"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"2023-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}